Medical Cannabis for Multiple Sclerosis - Spasticity, Pain and Other Symptoms

Multiple sclerosis (MS) is a chronic disease with no cure. But some symptoms - especially spasticity and neuropathic pain - respond to cannabinoid treatment better than many standard medications. Medical cannabis for MS is one of the most thoroughly documented indications in the entire field of cannabinoid neurology and psychiatry.

An important note upfront: cannabis relieves symptoms - it does not treat MS or halt disease progression. That role belongs to disease-modifying therapies (DMTs) managed by a neurologist. Cannabis enters the picture as supportive treatment - alongside, not instead of, conventional therapy. Below you will find an honest account of what you can realistically expect to gain, and what you should not.

MS has a highly variable course - one patient struggles mainly with spasticity, another with pain, yet another with bladder dysfunction. Cannabinoids act on several of these problems simultaneously, though with varying levels of evidence:

An important perspective: improvement is individual. Some patients experience clear relief, in others the effect is moderate or absent. There is no way to predict in advance how you will respond - which is why a cautious trial under medical supervision is essential.

Spasticity in MS is tension that does not relent. The leg and trunk muscles stay rigid, pain accompanies every movement, and nocturnal spasms wake the patient from sleep. Standard medications - baclofen, tizanidine - help, but are not always sufficient, and at higher doses cause excessive weakness.

This is where cannabinoids have an advantage. A 2024 meta-analysis covering 9 clinical trials in over 2,500 MS patients demonstrated statistically and clinically significant improvement in spasticity with cannabinoid therapy. Studies show improvement in patient-rated spasticity scales of up to 30-45% compared to placebo.

The mechanism: the endocannabinoid system (ECS) regulates muscle tone via CB1 receptors in the spinal cord and brain. THC and CBD, by binding to these receptors, reduce the excessive neural excitation responsible for spasticity. The effect differs from baclofen (which acts via GABA-B receptors) - which is why the two therapies can complement each other.

More on the mechanism of action in spasticity - in the context of strokes and spinal cord injuries - is described in our article medical cannabis for spasticity after stroke and spinal injuries.

Nabiximols (Sativex) is a ready-made cannabis-based medicine approved by the EMA specifically for relieving spasticity in MS when standard medications are insufficient. This is significant - we are not talking about an "alternative" preparation, but a drug with official registration in dozens of European countries.

Sativex contains THC and CBD in an approximately 1:1 ratio (exactly 2.7 mg THC and 2.5 mg CBD per dose). It is administered as an oromucosal spray. Dosing is individualised during a titration phase (usually 2 weeks), up to a maximum of 12 doses per day.

Key results from Sativex registration trials: at week 16 of treatment, more than 30% reduction in spasticity was achieved by approximately 74% of actively treated patients versus 51% in the placebo group. In Poland Sativex is registered but availability and reimbursement can be problematic - which is why many patients qualify for medical cannabis in the form of flower or oil with a similar THC:CBD ratio.

We discuss THC to CBD ratios and how to match them to specific symptoms in detail in the article THC:CBD ratios - how they are selected.

The endocannabinoid system (ECS) is a network of receptors and neurotransmitters that regulates many nervous system functions - muscle tone, pain perception, inflammation, and sleep rhythm. In MS the myelin sheath - the nerve's protective coating - is damaged, disrupting normal signal transmission and causing, among other things, spasticity and pain.

CB1 receptors, densely present in the spinal cord and brain areas controlling movement, are directly involved in regulating muscle tone. THC - acting on these receptors - lowers the excessive excitation of motor neurons. CBD acts differently: it does not bind strongly to CB1, but modulates inflammation and reduces anxiety, which can indirectly reduce pain perception.

In MS, upregulated expression of endocannabinoid receptors has also been found in inflamed tissues - suggesting the ECS itself is trying to "quench" excessive excitation. Exogenous cannabinoids (THC, CBD) support this mechanism.

Scientific evidence for cannabis in MS is mixed, but for spasticity it is solid. A systematic review and meta-analysis published in 2024 (Clinical Therapeutics) confirm that cannabinoids significantly improve subjectively rated spasticity in MS. The Cochrane review rates the evidence for spasticity as moderate certainty - a high standard in this field.

For neuropathic pain: reviews indicate real relief in some patients, but evidence quality is lower due to study heterogeneity and small sample sizes. Some individual trials showed no advantage over placebo.

What the research does NOT show: - No effect on disease progression - no study has shown that cannabis slows demyelination or reduces relapse frequency. - No effect on disability - symptom improvement does not translate into halting progressive disability. - No efficacy for tremor - attempts to treat intentional tremor in MS with cannabinoids have yielded negative results.

Conclusion: cannabis in MS is an effective symptomatic therapy for specific complaints - spasticity and pain. It is not a disease-modifying treatment.

In MS the most commonly used preparations have a THC:CBD ratio close to 1:1, which matches Sativex and is the best-studied combination for this indication. Forms available within the medical cannabis framework in Poland:

The "start low, go slow" principle is particularly important here: begin with low doses and increase gradually, monitoring effect and tolerance. In MS, many patients use preparations in the evening - improvement in sleep is one of the first effects felt.

Details on delivery forms and their differences are described in our article forms of medical cannabis administration, and dosing step by step in the article medical cannabis dosing.

Medical cannabis relieves MS symptoms in some patients. It does not treat the disease, does not halt demyelination, and does not replace disease-modifying therapy (DMT). Any change in neurological treatment requires consultation with a neurologist.

Specifically - cannabis will not replace: - DMT medications (interferons, glatiramer acetate, natalizumab, siponimod and others) - these are the only therapies that can slow MS progression. - Rehabilitation - exercise and physiotherapy have proven benefits for function in MS that cannabis does not replicate. - Baclofen or tizanidine - in many patients standard medications work well and are the first choice; cannabis enters when the response is insufficient.

Stopping neurological medications independently, without a neurologist's agreement, can lead to an MS relapse or more rapid accumulation of disability. Medical cannabis is a complement to therapy - not an alternative to it.

Studies on Sativex and other cannabinoid preparations in MS indicate that side effects are generally mild to moderate. The most common: dizziness, drowsiness, dry mouth, balance disturbances - particularly at the start of treatment, before the correct dose is established.

Relevant interactions in MS: - Baclofen + cannabinoids may potentiate each other's sedative effects - the doctor may need to adjust doses. - Interferon beta and other DMTs have no known clinically significant interactions with cannabinoids, but any polypharmacy requires monitoring. - MS patients who already have cognitive impairment should dose THC with particular caution - it may worsen memory and concentration difficulties.

The treatment discontinuation rate in studies was approximately 40% - due to both lack of efficacy and adverse effects. This means the therapy works for a clear proportion of patients, but not all - which is standard in symptomatic MS treatment. On chronic pain and the safety of cannabinoid therapy we write separately.

Qualification for medical cannabis in MS looks different from many other indications because it requires good coordination with the treating neurologist. Here is how the process works in practice:

Step 1 - Prepare your neurological documentation. MS diagnosis, current medication list (especially DMTs and symptomatic drugs such as baclofen), MRI results if available, description of current symptoms - spasticity, pain, sleep.

Step 2 - Qualification visit. The cannabis doctor assesses indications, rules out contraindications (rare in MS, but the presence of e.g. severe depression or psychosis requires caution) and establishes an initial dosing plan.

Step 3 - Therapeutic trial. Usually 4-8 weeks at a low dose, gradually increased. During this time you observe the effect on spasticity, pain and sleep.

Step 4 - Follow-up and possible optimisation. A follow-up visit (149 PLN) is the time to discuss effects, adjust dose or delivery form.

The first qualification visit costs 169 PLN. We see patients in person in Krakow, Bydgoszcz, Torun and Kielce. What the full prescription process looks like - step by step in a separate article. The costs of therapy over time - from the visit to the raw material - are described in the article how much does medical cannabis therapy cost in 2026.

Can medical cannabis replace Sativex? Sativex and medical cannabis (THC:CBD flower or oil) are preparations with a similar cannabinoid profile. The main differences are form, dosing precision, and availability. Sativex is registered for spasticity in MS, but in Poland it can be hard to access. Medical cannabis in a 1:1 ratio can serve a similar function - each case is assessed individually by the doctor.

Can I take cannabis alongside baclofen? Yes, but with caution - both preparations have muscle-relaxing and sedative effects. The doctor usually recommends maintaining the current baclofen dose at the start and monitoring for excessive drowsiness or weakness. Do not stop baclofen on your own.

Will cannabis help with tremor in MS? This is one of the MS symptoms where research results are disappointing - intentional tremor responds poorly to cannabinoids. Individual improvement cannot be ruled out, but this is not an indication with a strong evidence base.

How long does it take to see results? With spasticity, first effects can be noticed within a few days to a week of establishing the correct dose. A full assessment of efficacy usually requires 4-8 weeks of regular treatment. Sleep often improves faster than daytime spasticity.

Can I use cannabis if I have relapsing-remitting MS and am taking a DMT? Yes - medical cannabis does not affect DMT action and is not contraindicated in patients taking them. It is important that the cannabis doctor has the full medication list and that the neurologist is informed about the introduction of cannabinoid therapy.

What does it mean that MS is an off-label indication for cannabis in Poland? In Poland medical cannabis is prescribed on prescription by any licensed doctor - the MS indication is clinically justified and widely used, although formally the product is not registered for specific indications (as in the US or Germany). Find out about the full process in the article how to obtain a medical cannabis prescription. Insomnia as an MS symptom is also worth treating as a separate indication - we cover it in the article medical cannabis for insomnia.